Literature DB >> 3718818

Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.

B A Robinson, R D Clutterbuck, J L Millar, T J McElwain.   

Abstract

Verapamil had previously been shown to increase cellular melphalan uptake and cytotoxicity in fibrosarcomas, and increased the area under the blood concentration versus time curve (AUC) for melphalan in CBA mice. Verapamil (10 mg kg-1 i.p.) had no effect on the fractional distribution of cardiac output (FDCO), measured with 86Rb-rubidium chloride, to subcutaneous fibrosarcomas. 14C-Melphalan uptake by FS13 fibrosarcomas was increased 60 min after verapamil (10 mg kg-1 i.p.), but not after lower doses which did not affect the AUC. Flunarizine (5 mg kg-1 i.p.) also had no effect on FDCO to FS13 fibrosarcomas, and tended to increase 14C-melphalan content of blood and the fibrosarcomas and to promote growth delay by melphalan. Alcohol increased FDCO to FS13 fibrosarcomas, maximally at a 1:20 dilution in saline, but had no effect on 14C-melphalan uptake or growth delay. Thus, melphalan cytotoxicity correlated with tumour melphalan uptake, and both followed changes in the AUC for melphalan but not changes in FDCO. In these murine fibrosarcomas melphalan uptake and cytotoxicity were not limited by blood flow. In subcutaneous human melanoma HX46 xenografts, verapamil had no effect on the FDCO, nor on 14C-melphalan uptake, and did not affect blood 14C-melphalan levels, suggesting absence of effects on the AUC and on cellular uptake. Alcohol did not increase the FDCO to HX46 xenografts, providing evidence for a different vascular supply.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718818      PMCID: PMC2001383          DOI: 10.1038/bjc.1986.103

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Regional blood flow by fractional distribution of indicators.

Authors:  L A SAPIRSTEIN
Journal:  Am J Physiol       Date:  1958-04

2.  Studies on methods for determination of the distribution of cardiac output in the mouse.

Authors:  S Wetterlin; K F Aronsen; I Björkman; I Ahlgren
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

3.  Cardiac output distribution in the rat: comparison of rubidium and microsphere methods.

Authors:  P L Mendell; N K Hollenberg
Journal:  Am J Physiol       Date:  1971-12

4.  Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.

Authors:  D W Hedley; T J McElwain; J L Millar; M Y Gordon
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

5.  Comparison of microspheres and 86Rb+ as tracers of the distribution of cardiac output in rats indicates invalidity of 86Rb+-based measurements.

Authors:  D O Foster; M L Frydman
Journal:  Can J Physiol Pharmacol       Date:  1978-02       Impact factor: 2.273

6.  Mammary carcinoma cell population growth in preirradiated and unirradiated transplant sites. Viable tumor growth, vascularity, and the tumor-bed effect.

Authors:  K H Clifton; R Jirtle
Journal:  Radiology       Date:  1975-11       Impact factor: 11.105

7.  Effects of several vasoactive drugs on the vascular resistance of MT-W9B tumors in W/Fu rats.

Authors:  R Jirtle; K H Clifton; J H Rankin
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

8.  The effect of anaesthetics on blood perfusion in transplanted mouse tumours.

Authors:  G D Zanelli; P B Lucas; J F Fowler
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

9.  Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.

Authors:  J L Millar; B N Hudspith; T J McElwain; T A Phelps
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

10.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

View more
  3 in total

1.  Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data.

Authors:  Ali Khosravi; B Jayaram; Bahram Goliaei; Ali Masoudi-Nejad
Journal:  Mol Med       Date:  2019-06-20       Impact factor: 6.354

2.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

3.  Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.

Authors:  I J Stratford; G E Adams; J Godden; J Nolan; N Howells; N Timpson
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.